NCT03104192 is a NA clinical trial of Develop & Refine MOWI w/o Amulet in Obesity, sponsored by Dartmouth-Hitchcock Medical Center.

Who is sponsoring NCT03104192?

NCT03104192 is sponsored by Dartmouth-Hitchcock Medical Center.

What drugs are being tested in NCT03104192?

Interventions in NCT03104192: Develop & Refine MOWI w/o Amulet, MOWI Weight Loss Maintenance, Develop & Refine MOWI w Fitbit, Develop & Refine MOWI w Fitbit/Protein.

Is NCT03104192 still recruiting?

NCT03104192 is currently completed. Last updated 29 November 2022.

Are results published for NCT03104192?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-11-29 · How we verify

NCT03104192

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MOWI Research Pilot

Completed NA Results posted Last updated 29 November 2022

What this trial tests

NA trial testing Develop & Refine MOWI w/o Amulet in Obesity in 69 participants. Completed in 11 January 2020.

Timeline

1 September 2017

Primary endpoint
3 January 2019

11 January 2020

Quick facts

Lead sponsor	Dartmouth-Hitchcock Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	health services research
Enrollment	69
Start date	1 September 2017
Primary completion	3 January 2019
Estimated completion	11 January 2020
Sites	1 location across United States

Drugs / interventions tested

Develop & Refine MOWI w/o Amulet
MOWI Weight Loss Maintenance
Develop & Refine MOWI w Fitbit
Develop & Refine MOWI w Fitbit/Protein

Conditions studied

Obesity — all drugs for Obesity →

Sponsor

Dartmouth-Hitchcock Medical Center

Who can join

65 and older, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change in Grip Strength Primary · Baseline, 12 weeks

Assessed by a Jamar dynamometer. Sensor-based Thera-bands will measure data on strength change.

Group	Value	95% CI
Develop & Refine MOWI w/o Amulet (2A)	6.2	± 5.1
Develop & Refine MOWI w Fitbit (2B)	-2.6	± 5.2
Develop & Refine MOWI w Fitbit/Protein (2P)	4.3	± 3.4

Change in 5 Times Sit-to-Stand (STS) Primary · Baseline, 12 weeks

STS measures lower limb strength (minimal change 2.3 s).

Group	Value	95% CI
Develop & Refine MOWI w/o Amulet (2A)	-2.9	± 2.9
Develop & Refine MOWI w Fitbit (2B)	-1.5	± 1.7
Develop & Refine MOWI w Fitbit/Protein (2P)	-2.6	± 2.2

Change in Six-Minute Walk Test (6MWT) Primary · Baseline, 12 weeks

A surrogate for cardiovascular fitness that measures distance (normal 400-700m) related to function. A clinically important difference is 50-55m

Group	Value	95% CI
Develop & Refine MOWI w/o Amulet (2A)	47.5	± 83
Develop & Refine MOWI w Fitbit (2B)	39.3	± 51.6
Develop & Refine MOWI w Fitbit/Protein (2P)	31.8	± 27.8

Change in Gait Speed (m/s) Primary · Baseline, 12 weeks

Gait speed is measured by the time it takes to walk 20 meters. Gait speed predicts disability and mortality (significant change 0.1 m/s).

Group	Value	95% CI
Develop & Refine MOWI w/o Amulet (2A)	0.2	± 0.1
Develop & Refine MOWI w Fitbit (2B)	0.1	± 0.1
Develop & Refine MOWI w Fitbit/Protein (2P)	0.1	± 0.1

Change in Late-Life Function and Disability Instrument (LLFDI) Primary · Baseline, 12 weeks

LLFDI consists of a 32-item function and 16-item disability (life-task) scales that correlate with gait speed and lower limb function. Higher points indicate better function. Individual raw scores range from 0 to 80, scaled scores are 0 to 100. Each was assessed at baseline and at 12 weeks. We report the differences between baseline/follow-up. Positive score change reflect improved physical function.

Group	Value	95% CI
Develop & Refine MOWI w/o Amulet (2A)	8.6	± 8.6
Develop & Refine MOWI w Fitbit (2B)	9.0	± 8.6
Develop & Refine MOWI w Fitbit/Protein (2P)	6.3	± 6.9

Change in Behavioral Activation (Patient Activation Measure) Secondary · Baseline, 12 weeks post study

Patient Activation Measure (PAM) assesses knowledge, confidence and skill for managing health and grouped into 4 levels revealing insights into attitudes, motivators, behaviors \& outcomes. Higher points indicate better activation. Measures are scored 0-100 units. Scores below reflect changes between baseline and follow-up at 12-weeks. A positive change score indicates improvement in activation

Group	Value	95% CI
Develop & Refine MOWI w/o Amulet (2A)	9.2	± 11.3
Develop & Refine MOWI w Fitbit (2B)	18.8	± 14.5
Develop & Refine MOWI w Fitbit/Protein (2P)	11.0	± 10.8

Change in Subjective Health Status (PROMIS) Physical Secondary · Baseline, 12-weeks

Patient Reported Outcomes Measurement Information Systems (PROMIS) Global Short Form. PROMIS is a 10-item instrument capturing physical, mental and social aspects of quality of life having undergone quantitative appraisal and is non-proprietary. Higher points indicate better health. Raw scores are scaled to 0-100. 50 is the mean, 10 points indicates 1 standard deviation. Positive change scores listed below indicate an improvement in subjective health

Group	Value	95% CI
Develop & Refine MOWI w/o Amulet (2A)	3.0	± 4.4
Develop & Refine MOWI w Fitbit (2B)	6.4	± 5.3
Develop & Refine MOWI w Fitbit/Protein (2P)	2.3	± 3.6

Change in Weight in kg Secondary · Baseline, 12 weeks

Change in weight in kg

Group	Value	95% CI
Develop & Refine MOWI w/o Amulet (2A)	-4.3	± 3.2
MOWI Weight Loss Maintenance	-3.5238	± 9.11762
Develop & Refine MOWI w Fitbit (2B)	-5.8	± 3.1
Develop & Refine MOWI w Fitbit/Protein (2P)	-3.5	± 2.9

Change in Waist Circumference in cm Secondary · Baseline, 12 weeks post study

Change in waist and hip circumference in cm

Group	Value	95% CI
Develop & Refine MOWI w/o Amulet (2A)	-7.6	± 4.9
Develop & Refine MOWI w Fitbit (2B)	-6.4	± 6.3
Develop & Refine MOWI w Fitbit/Protein (2P)	-14.8	± 45.5

Average Steps/Expenditure Secondary · Mean steps over 12 week period of time

Average Steps will be measured over a 12 week period

Group	Value	95% CI
Develop & Refine MOWI w Fitbit (2B)	6494	± 3700
Develop & Refine MOWI w Fitbit/Protein (2P)	5127	± 3467

Community Healthy Activities Model Program for Seniors Physical Activity Questionnaire (CHAMPS) - Change in Number of Activities Secondary · Change Score between baseline and 12 weeks

CHAMPS is a self-reported tool in older adults that assesses activity levels and types -

Low intensity activities per week

Group	Value	95% CI
Develop & Refine MOWI w Fitbit (2B)	3.9	± 6.9
Develop & Refine MOWI w Fitbit/Protein (2P)	4.5	± 6.9

Moderate intensity activities per week

Group	Value	95% CI
Develop & Refine MOWI w Fitbit (2B)	8.6	± 9.2
Develop & Refine MOWI w Fitbit/Protein (2P)	5.2	± 9.1

Change in Body Composition - Lean Mass Secondary · Baseline, 12 weeks

Lean mass was assessed using bioelectrical impedance for 2P and 2B. This technique was not available for MOWI 2A participants and hence not measured

Group	Value	95% CI
Develop & Refine MOWI w Fitbit (2B)	-0.62	± 1.4
Develop & Refine MOWI w Fitbit/Protein (2P)	-1.44	± 1.45

Adverse events — posted to ClinicalTrials.gov

Time frame: 3 months. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Develop & Refine MOWI w/o Amulet (2A)

Serious: 1/9 (11%)

Deaths: 0/9

MOWI Weight Loss Maintenance

Serious: 0/23 (0%)

Deaths: 0/23

Develop & Refine MOWI w Fitbit (2B)

Serious: 3/14 (21%)

Deaths: 0/14

Develop & Refine MOWI w Fitbit/Protein (2P)

Serious: 1/14 (7%)

Deaths: 0/14

Serious adverse events (2 terms)

Reaction	System	Develop & Refine MOWI w/o …	MOWI Weight Loss Maintenance	Develop & Refine MOWI w Fi…	Develop & Refine MOWI w Fi…
Chest pain	Cardiac disorders	—	—	—	—
Headache	Nervous system disorders	—	—	—	—

Other adverse events (6 terms — click to expand)

Reaction	System	Develop & Refine MOWI w/o …	MOWI Weight Loss Maintenance	Develop & Refine MOWI w Fi…	Develop & Refine MOWI w Fi…
Musculoskeletal	Musculoskeletal and connective tissue disorders	—	—	—	—
Neurological	Nervous system disorders	—	—	—	—
Cardiovascular	Cardiac disorders	—	—	—	—
Gastrointestinal	Gastrointestinal disorders	—	—	—	—
Constitutional	General disorders	—	—	—	—
Respiratory	Respiratory, thoracic and mediastinal disorders	—	—	—	—

Most-reported serious reactions: Chest pain, Headache.

Data from ClinicalTrials.gov NCT03104192 adverse events section.

Sponsor's own description

The goal of this study is to conduct a program of pilot research aimed at developing and evaluating a technology-assisted wellness intervention for older adults with obesity.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Weight management intervention identifies association of decreased DNA methylation age with improved functional age measures in older adults with obesity.
Petersen CL, Christensen BC, Batsis JA. · · 2021 · cited 15× · PMID 33653394 · DOI 10.1186/s13148-021-01031-7
A Community-Based Feasibility Study of Weight-Loss in Rural, Older Adults with Obesity.
Batsis JA, Petersen CL, Cook SB, Al-Nimr RI, et al · · 2020 · cited 8× · PMID 32907522 · DOI 10.1080/21551197.2020.1817226
Relationship of Handgrip Strength and Asymmetry with Walking Ability in Older Adults with Excess Adiposity.
Cook SB, Chaudhry BA, Petersen CL, Mackenzie TA, et al · · 2024 · cited 2× · PMID 39007213 · DOI 10.1002/adbi.202400068
Adapting natural language processing and sentiment analysis methods for an intervention in older adults: Positive perceptions of health and technology.
Petersen CL, Li X, Stevens CJ, Gooding TL, et al · · 2023 · cited 1× · PMID 38116325 · DOI 10.4017/gt.2023.22.1.824.06

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Dartmouth-Hitchcock Medical Center trials

Trials by the same sponsor.

NCT07325474 — Plan and Protect: Safety Planning for Teens in Rural Emergency Departments · NA · not yet recruiting
NCT07428629 — Piloting an Insomnia Treatment in Patients With Ulcerative Colitis · NA · not yet recruiting
NCT06777511 — Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients · not yet recruiting
NCT07279116 — ABY-029 Head & Neck Trial · Phase 1 · not yet recruiting
NCT07063693 — ABY-029 Glioma Trial · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03104192 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dartmouth-Hitchcock Medical Center
Last refreshed: 29 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03104192.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing